RUNX1 Upregulation by Cytotoxic Drugs Promotes Apoptosis

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Mutations in the RUNX1 gene are linked to poor prognosis and chemotherapy resistance in hematologic malignancies like acute myeloid leukemia (AML).
• The precise mechanisms by which RUNX1 influences therapeutic outcomes in these cancers are not fully understood.

Purpose of the Study:

• To investigate the direct role of RUNX1 in the response of hematopoietic cells to cytotoxic chemotherapy agents.
• To elucidate the functional significance of the RUNX1 runt homology domain (RHD) in mediating cellular responses to DNA damage and chemotherapeutic agents.

Main Methods:

• Investigated RUNX1 expression in C57BL/6 mice and hematopoietic cell lines treated with cytotoxic agents.
• Analyzed RUNX1 upregulation in primary human AML cells after cytarabine treatment.
• Examined the effects of RUNX1 overexpression on cell proliferation, apoptosis, and DNA damage response.
• Assessed the functional impact of RHD-defective RUNX1 mutants on cellular sensitivity to ionizing radiation.

Main Results:

• Cytotoxic agents upregulated RUNX1 posttranscriptionally in vivo and in vitro, including in primary AML cells.
• Overexpression of RUNX1 restricted proliferation, promoted apoptosis, and augmented DNA damage response.
• RUNX1's anti-proliferative and pro-apoptotic functions required an intact RHD.
• RHD-defective RUNX1 mutants exhibited reduced or absent anti-proliferative/apoptotic activity and could confer resistance to ionizing radiation.

Conclusions:

• RUNX1 plays a novel role in mediating hematopoietic cell responses to cytotoxic agents, influencing proliferation, apoptosis, and DNA damage.
• RUNX1's function in this context is dependent on its RHD, explaining how mutations in this domain contribute to chemoresistance.
• Targeting RUNX1 pharmacologically presents a potential therapeutic strategy for hematologic malignancies.